BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients

NACompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

April 21, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Amyloidosis; Systemic
Interventions
DRUG

Doxycycline

Oral doxycycline 100mg twice daily

DRUG

Bortezomib

1.3mg/m2 of bortezomib on days 1, 8, 15 and 22 of a 35-day cycle

DRUG

Cyclophosphamide

300mg/m2 cyclophosphamide on days 1, 8, 15 and 22 of a 35-day cycle

DRUG

Dexamethasone

40mg of dexamethasone on days 1, 8, 15 and 22 of a 35-day cycle

Trial Locations (1)

100730

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
collaborator

Peking University First Hospital

OTHER

collaborator

Beijing Anzhen Hospital

OTHER

collaborator

Beijing Chao Yang Hospital

OTHER

collaborator

West China Hospital

OTHER

collaborator

Tongji Hospital

OTHER

collaborator

Union Hospital Affiliated with Tongji Medical College of HUST

UNKNOWN

collaborator

Shanghai Changzheng Hospital

OTHER

collaborator

Nanfang Hospital, Southern Medical University

OTHER

lead

Jian Li

OTHER

NCT03401372 - BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients | Biotech Hunter | Biotech Hunter